Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the rintatolimod European early access program (EAP) designed to enable access of the compound to ME/CFS patients has been extended to pancreatic cancer patients beginning in the Netherlands. The first patient was dosed and several other patients are in the queue to receive rintatolimod. MyTomorrows, Hemispherx’ exclusive service provider in Europe and Turkey, will manage all EAP activities relating to the extension in addition to its existing activities regarding early access use in chronic fatigue syndrome patients.
Hemispherx BioPharma shares reacted to the news, rising nearly 9% to $0.831 in early trading Wednesday.
“Pancreatic cancer patients generally have a poor prognosis and few therapeutic options. The cancer is commonly diagnosed at an advanced stage with a five-year survival rate of roughly only seven percent for all pancreatic cancer patients,” said Thomas Equels, CEO of Hemispherx, “We are happy to be able to expand our EAP to a patient population for this devastating malignancy with such a clearly unmet medical need.”
Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments.